A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05462106 |
|
Recruitment Status :
Recruiting
First Posted : July 18, 2022
Last Update Posted : February 21, 2024
|
Sponsor:
AC Immune SA
Collaborator:
Worldwide Clinical Trials
Information provided by (Responsible Party):
AC Immune SA
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer's Disease Prodromal Alzheimer's Disease Amyloid Plaque Beta-Amyloid Alzheimer's Disease in Down Syndrome | Biological: Placebo Biological: ACI-24.060 at Dose A Biological: ACI-24.060 at Dose B Biological: ACI-24.060 at Dose C Biological: ACI-24.060 at Dose D Biological: ACI-24.060 at Dose X Biological: ACI-24.060 at Dose Y | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE) |
| Actual Study Start Date : | June 21, 2022 |
| Estimated Primary Completion Date : | June 2026 |
| Estimated Study Completion Date : | June 2026 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Placebo for Study Part 1 (Prodromal AD)
Prodromal AD participants receive placebo at predefined time points over 48 weeks
|
Biological: Placebo
Administration of Placebo |
|
Experimental: ACI-24.060 at Dose A
Prodromal AD participants receive dose A of ACI-24.060 at predefined time points over 48 weeks
|
Biological: ACI-24.060 at Dose A
Administration of Dose A of ACI-24.060 |
|
Experimental: ACI-24.060 at Dose B (Optional)
Prodromal AD participants receive dose B of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
|
Biological: ACI-24.060 at Dose B
Administration of Dose B of ACI-24.060 |
|
Experimental: ACI-24.060 at Dose C (Optional)
Prodromal AD participants receive dose C of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
|
Biological: ACI-24.060 at Dose C
Administration of Dose C of ACI-24.060 |
|
Experimental: ACI-24.060 at Dose D (Optional)
Prodromal AD participants receive dose D of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
|
Biological: ACI-24.060 at Dose D
Administration of Dose D of ACI-24.060 |
|
Placebo Comparator: Placebo for Study Part 2 (Down syndrome)
Participants with Down syndrome receive placebo at predefined time points over 74 weeks
|
Biological: Placebo
Administration of Placebo |
|
Experimental: ACI-24.060 at Dose X
Participants with Down syndrome receive dose X of ACI-24.060 at predefined time points over 74 weeks. Dose X will be a dose already tested in Study Part 1.
|
Biological: ACI-24.060 at Dose X
Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1 |
|
Experimental: ACI-24.060 at Dose Y (Optional)
Participants with Down syndrome may optionally receive a dose Y of ACI-24.060 at predefined time points over 74 weeks.
|
Biological: ACI-24.060 at Dose Y
Administration of Dose Y of ACI-24.060 |
Primary Outcome Measures :
- Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related) [ Time Frame: From Screening to Week 74 (Study Part 1) ]
- Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related) [ Time Frame: From Screening to Week 100 (Study Part 2) ]
- Number of participants with abnormal MRI results [ Time Frame: From Baseline to Week 74 (Study Part 1) ]
- Number of participants with abnormal MRI results [ Time Frame: From Baseline to Week 100 (Study Part 2) ]
- Number of participants with abnormal physical and neurological examination results [ Time Frame: From Baseline to Week 74 (Study Part 1) ]
- Number of participants with abnormal physical and neurological examination results [ Time Frame: From Baseline to Week 100 (Study Part 2) ]
- Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: From Baseline to Week 74 (Study Part 1) ]
- Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: From Baseline to Week 100 (Study Part 2) ]
- Change from baseline in Anti-Abeta antibody titers in blood [ Time Frame: From Baseline to Week 100 (Study Part 2) ]
Secondary Outcome Measures :
- Change from baseline in Anti-Abeta antibody titers [ Time Frame: From Baseline to Week 74 (Study Part 1) ]
- Change from baseline on brain amyloid levels [ Time Frame: From Baseline to W100 (Study Part 2) ]Brain amyloid load measured via PET imaging. An increase indicates a worsening.
Other Outcome Measures:
- Change from baseline on brain amyloid levels [ Time Frame: From Baseline to W48 (Study Part 1) ]Brain amyloid load measured via PET imaging. An increase indicates a worsening.
- Change from baseline on tau levels [ Time Frame: From Baseline to W48 (Study Part 1) and to W100 (Study Part 2) ]Brain tau load measured via PET imaging. An increase indicates a worsening.
- Change from baseline in cognitive tests - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [ Time Frame: From Baseline to Week 74 (Study Part 1) ]The total scale index score ranges from 40 to 160. A higher score indicates a better outcome.
- Change from baseline in cognitive tests - Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 item (ADAS-Cog 13) [ Time Frame: From Baseline to Week 74 (Study Part 1) ]The score ranges from 0 to 85. A higher score indicates a worse outcome.
- Change from baseline in clinical function tests - Clinical Dementia Rating Scale (CDR) [ Time Frame: From Baseline to Week 74 (Study Part 1) ]The score ranges from 0 to 18. A higher score indicates a worse outcome.
- Change from baseline in cognitive tests - Modified Cued Recall Test (mCRT) [ Time Frame: From Baseline to Week 100 (Study Part 2) ]The modified CRT assesses verbal learning and episodic memory. The score ranges from X to Y. A higher score indicates a better outcome.
- Change from baseline in cognitive tests - Cambridge Cognitive Examination for Individuals with Down Syndrome (CAMCOG-DS2) [ Time Frame: From Baseline to Week 100 (Study Part 2) ]CAMCOG-DS measures cognitive decline. The total score ranges from 0 to 107. A higher score indicates a better outcome.
- Change from baseline in cognitive tests - Cambridge Neuropsychological Test Automated Battery-Paired Associates Learning (CANTAB-PAL) [ Time Frame: From Baseline to Week 100 (Study Part 2) ]The CANTAB-PAL assesses visual memory and new learning. A higher score indicates a better outcome.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 35 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Study Part 1
- Age ≥50 and ≤85 years at screening.
- Diagnosis of prodromal AD: MCI due to AD according to National Institute on Aging Alzheimer's Association (NIA-AA) criteria.
- PET scan at screening consistent with the presence of amyloid pathology.
- Clinical Dementia Rating (CDR)-Global Score of 0.5.
- Subjects either not taking any marketed treatment for AD or receiving a stable dose of an acetylcholinesterase inhibitor (ACHEI) and/or memantine for at least 2 months prior to baseline.
Study Part 2
- Age ≥35 and ≤50 years at screening (subjects with DS with age ≥35 and ≤39 years may be considered on the condition that there is prior evidence of amyloid results compatible with AD pathology at PET-scan and/or in biofluids).
- Male or female subjects with DS with a cytogenetic diagnosis being either trisomy 21 or complete unbalanced translocation of the chromosome 21.
- PET scan at screening consistent with the presence of amyloid pathology.
- Mild to moderate intellectual disability as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification.
- Subjects must have a study partner who has direct and regular contact, at least 10 hours per week, with the subject and who is able to provide reliable answers to questions related to the subject, according to the study investigator.
Exclusion Criteria:
- Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of the study vaccine (eg, moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.
- DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.
- History or presence of uncontrolled seizures. If history of seizures, they must be well controlled with no occurrence of seizures in the 2 years before study screening. The use of antiepileptic medications is permitted.
- Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks [TIAs], hemorrhagic and/or non-hemorrhagic stroke).
- History of meningitis or meningoencephalitis.
- History of moderate or severe traumatic brain injury.
- History of inflammatory neurological disorders.
- History or presence of immunological or inflammatory conditions, including neurological disorders, judged to be clinically significant by the investigator.
- History of severe allergic reaction (eg, anaphylaxis) including, but not limited to severe allergic reaction to previous vaccines, foods, and/or medications.
- Significant risk of suicide, defined using the C-SSRS as the subject answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behavior within the past 12 months.
- MRI scan at screening showing a single area of cerebral vasogenic edema, superficial siderosis, or evidence of a previous macro-hemorrhage or showing more than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"). Evidence of space occupying lesions other than benign meningioma of less than 1 cm diameter, more than 2 lacunar infarcts, or 1 single infarct larger than 1 cm in diameter. Screening MRI scan showing structural evidence of alternative pathology not consistent with AD and is considered to be at the origin of subject's symptoms.
- Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.
- Subjects with a positive Human Immunodeficiency Virus (HIV-1 and 2) test at screening.
- Subjects with clinical or laboratory evidence of active hepatitis B or C at screening (eg, HBV or HCV antigens).
- Subjects with positive syphilis serology consistent with active syphilis at screening.
- MRI examination cannot be done for any reason, including but not limited to metal implants contraindicated for MRI and/or severe claustrophobia.
- Any contraindication for PET scan imaging.
- Any contraindication to lumbar puncture in subjects undergoing this procedure (note: lumbar puncture is optional in subjects with DS).
- Previous treatment with ACI-24 or any other active immunotherapy against AD at any time in the past unless there is firm evidence that the subject received placebo only and the placebo formulation is not expected to induce any specific immune response.
- Previous treatment with any investigational and/or marketed passive immunotherapy against AD within 6 months before screening or 5 half-lives, whichever is longer, unless there is firm evidence that the subject received placebo only.
- Ongoing treatment with any approved anti-amyloid passive immunotherapy for Alzheimer's disease.
- Use of acetylcholinesterase inhibitor or glutamatergic drugs (eg, memantine, topiramate, lamotrigine) if not on stable dose for at least 2 months before screening.
- Any vaccine received within the 2 weeks before screening, including an anti-influenza or anti-COVID 19 vaccine received within 4 weeks before randomization.
- Subjects with treated hypothyroidism not on a stable dose of replacement medication for at least 2 months before screening and having clinically significant abnormal serum T4 and/or thyroid stimulating hormone at screening.
- Subjects undergoing lumbar puncture and being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower.
- Use of antidepressants (other than selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors at stable dose); typical antipsychotics; γ-aminobutyric acid agonists (eg, gabapentin); or stimulants (eg, methylphenidate, modafinil). Stable doses of atypical antipsychotics or benzodiazepines are only allowed if this is not considered to influence the safety and the efficacy of the study vaccine according to the site investigator and the sponsor medical monitor.
- Chronic use of opioid analgesics. A limited treatment duration for acute conditions until 24 hours before cognitive assessment is allowed.
-
Current use of immunosuppressant or immunomodulating drugs or their use within the 6 months before study screening. Current use of oral steroids or their use within the 3 months before study screening.
Additional Exclusion Criteria in Study Part 2
The following are exclusion criteria at the time of randomization but will not be considered as exclusionary after treatment assignment:
- Clinical diagnosis of AD dementia in DS as per International Classification of Diseases 10 (ICD-10).
- DSQIID >20.
- Intelligence quotient score <40 (KBIT-2).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05462106
Contacts
| Contact: Olivier Sol, MD | +41 21 345 9121 | clinicaltrials@acimmune.com | |
| Contact: Benedicte Le | +41 21 345 9121 | clinicaltrials@acimmune.com |
Locations
Show 17 study locations
Sponsors and Collaborators
AC Immune SA
Worldwide Clinical Trials
Investigators
| Principal Investigator: | Michael Rafii, MD | University of Southern California, Alzheimer's Therapeutic Research Institute, 9860 Mesa Rim Rd, San Diego, CA 92121, USA |
Additional Information:
| Responsible Party: | AC Immune SA |
| ClinicalTrials.gov Identifier: | NCT05462106 |
| Other Study ID Numbers: |
ACI-24-AD-DS-2102 2021-006195-17 ( EudraCT Number ) 2022-500069-29-00 ( Other Identifier: European Union Drug Regulatory Authorities Clinical Trial System ) |
| First Posted: | July 18, 2022 Key Record Dates |
| Last Update Posted: | February 21, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by AC Immune SA:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Prodromal Alzheimer's Disease |
Amyloid Plaque Beta-Amyloid Down syndrome Vaccine Immunogenicity |
Additional relevant MeSH terms:
|
Alzheimer Disease Down Syndrome Amyloidosis Syndrome Plaque, Amyloid Disease Pathologic Processes Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Proteostasis Deficiencies Metabolic Diseases Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Abnormalities, Multiple Congenital Abnormalities Chromosome Disorders Genetic Diseases, Inborn Pathological Conditions, Anatomical |